162 related articles for article (PubMed ID: 25912421)
1. A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers.
Giacomini A; Matarazzo S; Pagano K; Ragona L; Rezzola S; Corsini M; Di Salle E; Presta M; Ronca R
Oncotarget; 2015 May; 6(15):13790-802. PubMed ID: 25912421
[TBL] [Abstract][Full Text] [Related]
2. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer.
Ronca R; Alessi P; Coltrini D; Di Salle E; Giacomini A; Leali D; Corsini M; Belleri M; Tobia C; Garlanda C; Bonomi E; Tardanico R; Vermi W; Presta M
J Pathol; 2013 Jun; 230(2):228-38. PubMed ID: 23424081
[TBL] [Abstract][Full Text] [Related]
3. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors.
Leali D; Alessi P; Coltrini D; Ronca R; Corsini M; Nardo G; Indraccolo S; Presta M
Mol Cancer Ther; 2011 Sep; 10(9):1600-10. PubMed ID: 21764903
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide.
Leali D; Bianchi R; Bugatti A; Nicoli S; Mitola S; Ragona L; Tomaselli S; Gallo G; Catello S; Rivieccio V; Zetta L; Presta M
J Cell Mol Med; 2010 Aug; 14(8):2109-21. PubMed ID: 19627396
[TBL] [Abstract][Full Text] [Related]
5. Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells.
Ronca R; Di Salle E; Giacomini A; Leali D; Alessi P; Coltrini D; Ravelli C; Matarazzo S; Ribatti D; Vermi W; Presta M
Mol Cancer Ther; 2013 Dec; 12(12):2760-71. PubMed ID: 24130051
[TBL] [Abstract][Full Text] [Related]
6. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis.
Rusnati M; Camozzi M; Moroni E; Bottazzi B; Peri G; Indraccolo S; Amadori A; Mantovani A; Presta M
Blood; 2004 Jul; 104(1):92-9. PubMed ID: 15031207
[TBL] [Abstract][Full Text] [Related]
7. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.
Maruyama-Takahashi K; Shimada N; Imada T; Maekawa-Tokuda Y; Ishii T; Ouchi J; Kusaka H; Miyaji H; Akinaga S; Tanaka A; Shitara K
Prostate; 2008 May; 68(6):640-50. PubMed ID: 18213631
[TBL] [Abstract][Full Text] [Related]
8. Long Pentraxin-3 Modulates the Angiogenic Activity of Fibroblast Growth Factor-2.
Presta M; Foglio E; Churruca Schuind A; Ronca R
Front Immunol; 2018; 9():2327. PubMed ID: 30349543
[TBL] [Abstract][Full Text] [Related]
9. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo.
Camozzi M; Zacchigna S; Rusnati M; Coltrini D; Ramirez-Correa G; Bottazzi B; Mantovani A; Giacca M; Presta M
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1837-42. PubMed ID: 16020751
[TBL] [Abstract][Full Text] [Related]
10. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
11. Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis.
Leali D; Inforzato A; Ronca R; Bianchi R; Belleri M; Coltrini D; Di Salle E; Sironi M; Norata GD; Bottazzi B; Garlanda C; Day AJ; Presta M
Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):696-703. PubMed ID: 22267482
[TBL] [Abstract][Full Text] [Related]
12. A neutralizing anti-fibroblast growth factor 8 monoclonal antibody shows potent antitumor activity against androgen-dependent mouse mammary tumors in vivo.
Shimada N; Ishii T; Imada T; Takaba K; Sasaki Y; Maruyama-Takahashi K; Maekawa-Tokuda Y; Kusaka H; Akinaga S; Tanaka A; Shitara K
Clin Cancer Res; 2005 May; 11(10):3897-904. PubMed ID: 15897591
[TBL] [Abstract][Full Text] [Related]
13. Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy.
Ronca R; Giacomini A; Di Salle E; Coltrini D; Pagano K; Ragona L; Matarazzo S; Rezzola S; Maiolo D; Torrella R; Moroni E; Mazzieri R; Escobar G; Mor M; Colombo G; Presta M
Cancer Cell; 2015 Aug; 28(2):225-39. PubMed ID: 26267536
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides.
Leali D; Alessi P; Coltrini D; Rusnati M; Zetta L; Presta M
Curr Pharm Des; 2009; 15(30):3577-89. PubMed ID: 19860702
[TBL] [Abstract][Full Text] [Related]
15. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
16. Screening a phage display library for a novel FGF8b-binding peptide with anti-tumor effect on prostate cancer.
Wang W; Chen X; Li T; Li Y; Wang R; He D; Luo W; Li X; Wu X
Exp Cell Res; 2013 May; 319(8):1156-64. PubMed ID: 23466786
[TBL] [Abstract][Full Text] [Related]
17. Syndecan-1 regulates FGF8b responses in S115 mammary carcinoma cells.
Viklund L; Vorontsova N; Henttinen T; Salmivirta M
Growth Factors; 2006 Jun; 24(2):151-7. PubMed ID: 16801134
[TBL] [Abstract][Full Text] [Related]
18. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3.
Camozzi M; Rusnati M; Bugatti A; Bottazzi B; Mantovani A; Bastone A; Inforzato A; Vincenti S; Bracci L; Mastroianni D; Presta M
J Biol Chem; 2006 Aug; 281(32):22605-13. PubMed ID: 16769728
[TBL] [Abstract][Full Text] [Related]
19. The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells.
Song Z; Powell WC; Kasahara N; van Bokhoven A; Miller GJ; Roy-Burman P
Cancer Res; 2000 Dec; 60(23):6730-6. PubMed ID: 11118059
[TBL] [Abstract][Full Text] [Related]
20. An FGF8b-mimicking peptide with potent antiangiogenic activity.
Lin X; Song L; He D; Zeng X; Wu J; Luo W; Yang Q; Wang J; Wang T; Cai J; Lin Y; Lai F; Peng W; Wu X
Mol Med Rep; 2017 Jul; 16(1):894-900. PubMed ID: 28560418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
